Genmab — August 2018
-
I know that after the Callisto failure things changed on the solid side. Just have a question one step back on why Genmab was targetting that market. I know the lung cancer market is a huge market. On the other hand there are other drugs/ther being developed which are a lot cheaper. From a cost/effectiveness (Dara) point of view, was it interesting enough to target it in the first place, ie could Dara have made a big difference vs the other new medicines? Didn't look at the ph1 data in detail.
-
FL...Welcome to Proinvestor. Maybe you should find a different alias than F L. It will easily be confused with E L.
-
God morgen
-
God morgen.
-
God Morgen
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind